Patel Naimish sold $211K of CRSP

Patel Naimish (Chief Medical Officer) sold 3,786 shares of CRISPR Therapeutics AG (CRSP) at $55.62 ($0.21M total) on 2026-05-29.

Original reporting
SEC EDGAR · Patel Naimish
Published Jun 1, 2026, 9:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 1, 2026, 9:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CRSP
Neutral
medium confidence
Mentioned
$CRSP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRSPNeutralLow
01

Why it matters

This provides a datapoint on insider behavior but does not introduce new clinical, regulatory, or financial information.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to be a primary driver of price.

03

What to watch

No 10b5-1 plan is cited, but the article provides no reason for the sale, tax context, or whether other insiders executed offsetting trades.

Relevance 6/10Novelty 3/10Timing: SEC Form 4 filed 2026-06-01 (sale dated 2026-05-29).

Background

The article is an SEC Form 4 insider transaction disclosure for CRISPR Therapeutics (CRSP).

Company-level read

Ticker impact

$CRSPNeutralMedium confidence
Context

CRSP’s CMO Patel Naimish sold 3,786 shares in an open-market transaction disclosed via SEC Form 4 on 2026-05-29.

Expected impact

Likely limited immediate impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is an officer open-market sale with no stated link to new clinical/regulatory or financial developments; 10b5-1 plan is explicitly marked as not pre-arranged, but insider sales alone rarely drive durable repricing without corroborating news.

Market effects

Minimal; this is company-specific insider activity with no disclosed sector-wide catalyst.

None indicated beyond US-listed biotech sentiment.

None indicated.

Counterpoint

The sale may be routine liquidity/portfolio rebalancing rather than a bearish view, especially given the small absolute size versus typical insider holdings.

Key entities

  • CRISPR Therapeutics AG

    Subject of the SEC Form 4 insider sale disclosure.

  • Patel Naimish

    Chief Medical Officer who sold shares via open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRSPMed

Seawolf Therapeutics San Diego $100M Sanofi DNA Deal

Seawolf Therapeutics, a San Diego biotech, raised $100M and partnered with Sanofi for a deal potentially worth $1.2B. The company's TRIDENT platform aims to enable repeat dosing of gene therapies. Seawolf's lead program targets metabolic diseases, with human trials expected by 2028. Investors include Eli Lilly, Novartis Venture Fund, and CRISPR Therapeutics.

$CRSPHighAI 8/10

Piper Sandler reiterates CRISPR Therapeutics stock rating at overweight

Piper Sandler maintained an Overweight rating and $110 price target for CRISPR Therapeutics (CRSP) after positive clinical data presentations. CTX310 showed significant reductions in lipid parameters, while zugo-cel demonstrated high response rates in various diseases. CRSP reported Q3 2026 sales of $99M for CASGEVY and holds $2.36B in cash. Analysts have mixed views on its valuation and price targets.

$CRSPMedAI 8/10

CRISPR Therapeutics reports trial results for gene therapy CTX310

CRISPR Therapeutics (CRSP) reported Phase 1b trial results for CTX310, a gene therapy for severe hypertriglyceridemia. The trial showed significant reductions in triglycerides, ANGPTL3 protein, and other cholesterol markers. No serious adverse events were reported. The FDA has granted RMAT designations to CTX310 for this indication and for elevated LDL cholesterol.